Assessment: The enVista ENVY (EN) intraocular lens (IOL) provides up to 4 D of continuous visual range with enhanced tolerance to dysphotopsia. This retrospective case series documents healthcare providers' real-world experience of using the EN IOL, including satisfaction, IOL utilization patterns, and patient outcomes.

METHODS: This sub-analysis of a multicentre, cross-sectional retrospective case series documents real-world outcomes following implantation with the enVista ENVY (EN) full visual range intraocular lens (IOL). Thirteen HCPs in the USA (n=12) and Canada (n=1) provided a convenience sample of EN electronic medical record cases using a standardized case report form to document real-world clinical performance. Procedures were conducted between 14 October 2024 and 30 July 2025. Key outcome measures included corrected and uncorrected distance and uncorrected intermediate and near visual acuity (CDVA, UDVA, UIVA, UNVA), refractive outcomes, and adverse events (AEs).

RESULTS: The analysis included 94 patients (144 eyes); 44 unilateral, 50 bilateral. The mean±SD spherical equivalent target was 0.05±1.91 (n=135). Following surgery, a monocular CDVA of ≤20/25 was achieved in 98% of eyes (116/118); UDVA of ≤20/32 in 88% of eyes (117/133), UIVA of ≤20/32 in 91% of eyes (53/58); UNVA of ≤J2 in 78% of eyes (88/113). Binocular CDVA of ≤20/25 was achieved in 100% of patients (42/42). Mean±SD MRSE was −0.09±0.38 (n=116). No serious AEs were reported. No patients reported glistening.

CONCLUSION: In this multicenter, cross-sectional, retrospective study, the EN IOL provided excellent distance, intermediate, and near visual acuity for most patients, with no glistening or serious AEs reported.